NCT02852564View on ClinicalTrials.gov

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Bladder Cancer
Interventions
DRUG

Ethacrynic Acid

One oral dose at 50 mg prior to bladder tumor removal surgery

Trial Locations (1)

66160

The University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

University of Kansas Medical Center

OTHER

lead

Eugene Lee, MD

OTHER

NCT02852564 - Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | Biotech Hunter | Biotech Hunter